跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 15 条关于
“NovelMed”
全部
15
临床试验
0
药物
5
机构
2
资讯
8
去年
Ruxoprubart Receives FDA IND Clearance for Phase II Trials in IgAN and Dermatomyositis
6个月前
NovelMed's Ruxoprubart Achieves 100% Transfusion Independence in PNH Phase II Trial, Gains Regulatory Clearance for Subcutaneous Dosing
去年
Ruxoprubart Shows Promising Phase II Results as Novel Monotherapy for Paroxysmal Nocturnal Hemoglobinuria
去年
Complement Inhibitors Show Promise in Diverse Clinical Trials
去年
Ruxoprubart Achieves Primary Endpoints in Phase 2 Trial for Paroxysmal Nocturnal Hemoglobinuria
7个月前
Novartis Reports Positive Phase III Results for Fabhalta in Rare Kidney Disease C3 Glomerulopathy
去年
Paroxysmal Nocturnal Hemoglobinuria Pipeline Shows Robust Development with 25+ Therapies from Leading Pharmaceutical Companies
去年
Novartis' FABHALTA Poised to Transform Treatment Landscape for Multiple Complement-Mediated Diseases